Biogen’s big Alzheimer’s drug win fails to boost the stock as analysts see slow Leqembi rollout
July 07, 2023 at 10:49 AM EDT
Milestone Leqembi approval is “a mixed bag,” analysts say, given drug label's risk warnings and infusion-center bottlenecks.
